{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:32:14Z","timestamp":1793842334290,"version":"4.6.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007406","name":"BBVA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:16:58Z","timestamp":1777562218000},"page":"1049-1065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8492-5195","authenticated-orcid":false,"given":"O.","family":"Mirallas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-1211","authenticated-orcid":false,"given":"G.","family":"Pretelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-675X","authenticated-orcid":false,"given":"P.","family":"Jim\u00e9nez-Labaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hernando-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1200-9095","authenticated-orcid":false,"given":"H.","family":"Nathan Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-1089","authenticated-orcid":false,"given":"P.N.","family":"Selvadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tall\u00f3n de Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martin-Liberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"K.J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"S.","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.04.015_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2026.04.015_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2026.04.015_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CJI.0b013e3180336787","article-title":"IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells","volume":"30","author":"Ahmadzadeh","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.annonc.2026.04.015_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/eji.200636435","article-title":"Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells","volume":"37","author":"Wang","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression: implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.annonc.2026.04.015_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4 mediated transendocytosis of co-stimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.annonc.2026.04.015_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.immuni.2010.09.006","article-title":"Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation","volume":"33","author":"Yokosuka","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.04.015_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.immuni.2016.01.013","article-title":"Interleukin-35 limits anti-tumor immunity","volume":"44","author":"Turnis","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/2159-8290.CD-12-0527","article-title":"TGF-\u03b2 signaling in myeloid cells is required for tumor metastasis","volume":"3","author":"Pang","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.04.015_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib19","series-title":"Signaling Mechanisms Regulating T Cell Diversity and Function","article-title":"Models of Regulatory T Cell Alterations and Systemic Autoimmunity","author":"Cho","year":"2018"},{"key":"10.1016\/j.annonc.2026.04.015_bib20","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0625.2011.01260.x","article-title":"Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma","volume":"20","author":"Knol","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annonc.2026.04.015_bib22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1183\/13993003.00176-2014","article-title":"Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer","volume":"46","author":"O\u2019Callaghan","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.annonc.2026.04.015_bib23","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","article-title":"The expression of the regulatory T cell\u2013specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer","volume":"11","author":"Wolf","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12032-011-9903-2","article-title":"The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers","volume":"29","author":"Sun","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib25","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2026.04.015_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2026.04.015_bib27","doi-asserted-by":"crossref","first-page":"62312","DOI":"10.18632\/oncotarget.17602","article-title":"Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2026.04.015_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer","volume":"27","author":"Salama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0192623309354110","article-title":"Roles for inflammation and regulatory T cells in colon cancer","volume":"38","author":"Erdman","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.015_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clim.2013.05.003","article-title":"The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer","volume":"148","author":"Li","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib31","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/ijc.24989","article-title":"High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients","volume":"126","author":"Frey","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.immuni.2011.12.012","article-title":"Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells","volume":"36","author":"Miyao","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00262-014-1581-4","article-title":"Foxp3 expression in T regulatory cells and other cell lineages","volume":"63","author":"Devaud","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2026.04.015_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.015_bib36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2012.09.010","article-title":"T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development","volume":"37","author":"Ohkura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/ni.3646","article-title":"Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment","volume":"18","author":"Kitagawa","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ni.3812","article-title":"MLL4 prepares the enhancer landscape for Foxp3 induction via chromatin looping","volume":"18","author":"Placek","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2013.03.002","article-title":"Development and maintenance of regulatory T cells","volume":"38","author":"Ohkura","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib40","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.4049\/jimmunol.1203473","article-title":"Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus","volume":"190","author":"Toker","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib41","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ni.3085","article-title":"The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells","volume":"16","author":"Vasanthakumar","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib45","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.4049\/jimmunol.2001184","article-title":"BATF regulates T regulatory cell functional specification and fitness of triglyceride metabolism in restraining allergic responses","volume":"206","author":"Xu","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-019-14112-2","article-title":"Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell differentiation and homeostasis","volume":"11","author":"Sidwell","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2026.04.015_bib47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature08750","article-title":"Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate","volume":"463","author":"Zheng","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.04.015_bib48","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2014.07.030","article-title":"Function of a Foxp3 cis-element in protecting regulatory T cell identity","volume":"158","author":"Li","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104471","article-title":"CRISPR\/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells","volume":"371","author":"Wilk","year":"2022","journal-title":"Cell Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib50","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.0050038","article-title":"Epigenetic control of the foxp3 locus in regulatory T cells","volume":"5","author":"Floess","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.annonc.2026.04.015_bib51","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s10753-024-02031-4","article-title":"Targeted demethylation of FOXP3-TSDR enhances the suppressive capacity of STAT6-deficient inducible T regulatory cells","volume":"47","author":"Arroyo-Olarte","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.annonc.2026.04.015_bib52","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","article-title":"Adenosine signaling and the immune system: when a lot could be too much","volume":"205","author":"Antonioli","year":"2019","journal-title":"Immunol Lett"},{"key":"10.1016\/j.annonc.2026.04.015_bib54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib55","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coi.2009.05.021","article-title":"Developmental plasticity of Th17 and Treg cells","volume":"21","author":"Lee","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib57","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.0811556106","article-title":"Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity","volume":"106","author":"Komatsu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2026.04.015_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","article-title":"Molecular antagonism and plasticity of regulatory and inflammatory T cell programs","volume":"29","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib59","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","article-title":"Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells","volume":"112","author":"Koenen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2026.04.015_bib60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2009.10.001","article-title":"Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection","volume":"31","author":"Oldenhove","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib61","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib64","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s12967-024-05518-8","article-title":"Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib65","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jtho.2025.02.029","article-title":"Selective depletion of CCR8+ Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib66","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1535-7163.MCT-22-0570","article-title":"S-531011, a novel anti-human CCR8 antibody, induces potent antitumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells","volume":"22","author":"Nagira","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2026.04.015_bib67","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A1454","article-title":"1399 ZL 1218 targets the most suppressive intratumoral Treg subpopulation to avoid peripheral toxicities","author":"Zhang","year":"2022"},{"issue":"Suppl","key":"10.1016\/j.annonc.2026.04.015_bib68","article-title":"1008P Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors","volume":"35","author":"Bazo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000967","article-title":"Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy","volume":"8","author":"Chuckran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature12428","article-title":"Regulatory T cell stability is maintained by a neuropilin-1:semaphorin-4a axis","volume":"501","author":"Delgoffe","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.04.015_bib71","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1038\/srep07767","article-title":"Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in na\u00efve mice","volume":"5","author":"Singh","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2026.04.015_bib72","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1126\/science.aad0616","article-title":"Stable inhibitory activity of regulatory T cells requires the transcription factor Helios","volume":"350","author":"Kim","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.annonc.2026.04.015_bib73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/eji.202149318","article-title":"Helios is a marker, not a driver,of human Treg stability","volume":"52","author":"Lam","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib74","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1158\/1078-0432.CCR-24-0729","article-title":"KIR2DL2\/DL3+ NKs and Helios+ Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer","volume":"30","author":"Santagata","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/1471-2407-11-515","article-title":"Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma","volume":"11","author":"Telang","year":"2011","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.015_bib76","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO-24-01549","article-title":"Efficacy and safety of denileukin diftitox-Cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"43","author":"Foss","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.015_bib77","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"issue":"30","key":"10.1016\/j.annonc.2026.04.015_bib78","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, Phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.015_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.015_bib80","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.015_bib81","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2767-9764.CRC-24-0638","article-title":"Safety and antitumor activity of a novel aCD25 Treg depleter RG6292 as a single agent and in combination with atezolizumab in patients with solid tumors","volume":"5","author":"Gambardella","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"8_Supplement_2","key":"10.1016\/j.annonc.2026.04.015_bib82","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT067","article-title":"Abstract CT067: Preliminary safety and efficacy results of an anti-CD25 monoclonal antibody (BA1106) in patients with advanced solid tumors: the first-in-human study","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.015_bib83","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.annonc.2026.04.015_bib84","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2025.43.16_suppl.3553","article-title":"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti\u2013CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.015_bib85","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2166","article-title":"1027P An open-label, multicenter, phase I\/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)","volume":"34","author":"Cho","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.04.015_bib87","article-title":"718 Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and\/or metastatic solid tumors","volume":"10","author":"Cho","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.015_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291772","article-title":"Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors","volume":"18","author":"Fujikawa","year":"2023","journal-title":"PLOS One"},{"issue":"17","key":"10.1016\/j.annonc.2026.04.015_bib89","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-0328","article-title":"Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a Phase I study","volume":"26","author":"Zamarin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.annonc.2026.04.015_bib90","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the anti-CC chemokine Receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.015_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010634","article-title":"Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors","volume":"13","author":"Jinushi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib92","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/JCO.2025.43.16_suppl.4010","article-title":"Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: results from phase 1\/2 studies","volume":"43","author":"Gong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.annonc.2026.04.015_bib93","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2024.42.16_suppl.2504","article-title":"Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: results from phase 1\/2 studies","volume":"42","author":"Gong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.annonc.2026.04.015_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3076","article-title":"Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors","volume":"43","author":"Doi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/1535-7163.MCT-25-0367","article-title":"CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses","volume":"25","author":"Wang","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2026.04.015_bib96","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT038","article-title":"Abstract CT038: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors","volume":"85","author":"Worden","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib97","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-22-0339","article-title":"Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab, or nivolumab in patients with advanced solid tumors","volume":"28","author":"Davar","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib98","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-20-2886","article-title":"Phase I study of MK-4166, an anti-human glucocorticoid-induced TNF receptor antibody, alone or with pembrolizumab in advanced solid tumors","volume":"27","author":"Papadopoulos","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.annonc.2026.04.015_bib99","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1158\/1078-0432.CCR-20-0452","article-title":"Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors","volume":"26","author":"Balmanoukian","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010777","article-title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1\/2 non-randomized ARTISTRY-1 trial","volume":"13","author":"Calvo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib103","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.997376","article-title":"PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis","volume":"14","author":"Pereira","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib105","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.4049\/jimmunol.2001334","article-title":"Anti-PD-1 checkpoint therapy can promote the function and survival of regulatory T cells","volume":"207","author":"Vick","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib106","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/cas.15756","article-title":"Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity","volume":"114","author":"Watanabe","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.annonc.2026.04.015_bib107","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib108","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","article-title":"CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion","volume":"112","author":"Kavanagh","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.015_bib109","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/2159-8290.CD-24-1390","article-title":"Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade","volume":"15","author":"Jiang","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.04.015_bib110","article-title":"A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors","volume":"4","author":"Frentzas","year":"2023","journal-title":"Cell Rep Med"},{"issue":"Suppl","key":"10.1016\/j.annonc.2026.04.015_bib111","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0090-8258(22)01293-8","article-title":"Efficacy and safety of cadonilimab, an anti-PD-1\/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)","volume":"166","author":"Wu","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib112","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib113","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.annonc.2026.04.015_bib114","doi-asserted-by":"crossref","first-page":"S1180","DOI":"10.1016\/j.annonc.2023.09.1338","article-title":"Abstract 2311: population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2\u03b2\u03b3R and CTLA4","volume":"34","author":"Chae","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib116","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/eji.201343451","article-title":"Modulation of Treg cells\/T effector function by GITR signaling is context-dependent","volume":"43","author":"Ephrem","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib117","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-22-1489","article-title":"GITR antibodies in cancer: not ready for prime time","volume":"28","author":"Hernandez-Guerrero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib118","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.04.015_bib119","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120626","article-title":"Phosphoinositide 3-kinase \u03b4 inhibition promotes antitumor responses but antagonizes checkpoint inhibitors","volume":"3","author":"Lim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.annonc.2026.04.015_bib120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.04.015_bib121","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2024.42.16_suppl.2664","article-title":"Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors","volume":"42","author":"Patnaik","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.015_bib122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10238-024-01362-8","article-title":"Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody","volume":"24","author":"Roider","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib123","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib124","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04939.x","article-title":"Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells","volume":"1174","author":"Rech","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.annonc.2026.04.015_bib125","series-title":"Zinbryta (daclizumab)","year":"2018"},{"key":"10.1016\/j.annonc.2026.04.015_bib126","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.ymthe.2024.09.010","article-title":"A CD25\u00d7TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion","volume":"32","author":"Wei","year":"2024","journal-title":"Mol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.annonc.2026.04.015_bib127","first-page":"A1","article-title":"1045 PF-08046032: a novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors","volume":"12","author":"Abdelhamed","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.015_bib128","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-25-0101","article-title":"PF-08046032: a novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors","volume":"24","author":"Abdelhamed","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2026.04.015_bib129","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1538-7445.AM2024-4079","article-title":"Abstract 4079: EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment","volume":"84","author":"Kotsias","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib130","article-title":"674 Preferential tumor retention of EGL-001, a CTLA-4\/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study","volume":"12","author":"Kotsias","year":"2024","journal-title":"J Immunother. Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib131","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib132","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib133","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2026.04.015_bib134","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.annonc.2026.04.015_bib135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib136","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"key":"10.1016\/j.annonc.2026.04.015_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.coi.2009.05.007","article-title":"Plasticity of CD4(+) FoxP3(+) T cells","volume":"21","author":"Zhou","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib139","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2026.04.015_bib140","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.04.015_bib141","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41590-021-00958-6","article-title":"Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy","volume":"22","author":"Eschweiler","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib142","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.annonc.2026.04.015_bib143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000764","article-title":"Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib144","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.4049\/jimmunol.1400481","article-title":"IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R\/ST2+ regulatory T cells","volume":"193","author":"Matta","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib145","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.4049\/jimmunol.1301369","article-title":"Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy","volume":"192","author":"Kim","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.annonc.2026.04.015_bib146","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29351","article-title":"Potential utility of the pan-Bcl-2 inhibitor GX15\u2013070 (obatoclax) in cancer immunotherapy","volume":"3","author":"Kim","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2026.04.015_bib147","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","article-title":"Arginase I\u2013producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib148","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.015_bib149","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-23-0517","article-title":"CD4+ regulatory T cells in human cancer: subsets, origin, and molecular regulation","volume":"12","author":"Swatler","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.015_bib150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013072","article-title":"Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis","volume":"13","author":"Jimenez-Labaig","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.04.015_bib151","article-title":"Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity","author":"Bockman","year":"2025","journal-title":"bioRxiv"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:27Z","timestamp":1785283167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":150,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0923753426001602"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}